Mean of 19.5, 17.1, and 43.3% of participants did not maintain continuity of use of glucose, BP, lipid medications
Mean of 19.5, 17.1, and 43.3% of participants did not maintain continuity of use of glucose, BP, lipid medications
The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.
The approval was based on data from a clinical program that included 23 clinical trials enrolling more than 5000 adults with type 2 diabetes mellitus.
Rybelsus is a glucagon-like peptide receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Layered approach involves initially combining lifestyle interventions, self-management, and first-line pharmacotherapy
Strong recommendations include use of glucagon preparations that do not need reconstitution, real-time CGM for those receiving multiple daily injections
Mexican American adults receiving insulin less likely than non-Hispanic Whites to achieve glycemic control
Findings seen among subgroup of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Reduced risk seen for total knee replacement and total hip replacement with metformin use